Search
Tropifexor
go.drugbank.com/drugs/DB16343InvestigationalTropifexor is under investigation in clinical trial NCT02516605 (A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients).
Velsecorat
go.drugbank.com/drugs/DB16347InvestigationalVelsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients
Zampilimab
go.drugbank.com/drugs/DB16381InvestigationalZampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft
Bexmarilimab
go.drugbank.com/drugs/DB16383InvestigationalBexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).
Zansecimab
go.drugbank.com/drugs/DB16389InvestigationalZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
Daxdilimab
go.drugbank.com/drugs/DB16391InvestigationalDaxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Modakafusp alfa
go.drugbank.com/drugs/DB16399InvestigationalModakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory
BNT-162A1
go.drugbank.com/drugs/DB16402InvestigationalBNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
go.drugbank.com/drugs/DB16431ExperimentalReceptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated
MVA-SARS-2-S
go.drugbank.com/drugs/DB16432InvestigationalMVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines … MVA-SARS-2-S is a COVID-19 vaccine candidate that contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein[L30453].